7.91

3.54% -0.29

After Hours: 7.91

Vanda Pharmaceuticals Inc (VNDA)

Overview News Price History Option Chain Financials Discussions Forecast

Vanda Pharmaceuticals Inc stock is traded at $7.91, with a volume of 967.10K. It is down -3.54% in the last 24 hours and up +9.41% over the past month. Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Previous Close:

$8.20

Open:

$8.34

24h Volume:

967.10K

Relative Volume:

0.37

Market Cap:

$467.54M

Revenue:

$192.64M

Net Income/Loss:

$2.51M

P/E Ratio:

150.95

EPS:

0.0524

Net Cash Flow:

$12.42M

1W Performance:

-8.02%

1M Performance:

+9.41%

6M Performance:

+71.58%

1Y Performance:

+54.19%

1-Day Range:

$7.77

$8.38

1-Week Range:

$7.66

$9.005

52-Week Range:

$3.8092

$9.60

Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile

Name

Vanda Pharmaceuticals Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

202-734-3400

Address

2200 PENNSYLVANIA AVE NW, WASHINGTON

Employee

533

Twitter

Next Earnings Date

2025-05-02

Latest SEC Filings

VNDA's Discussions on Twitter

Compare VNDA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VNDA Vanda Pharmaceuticals Inc	7.91	484.69M	192.64M	2.51M	12.42M	0.0524
VRTX Vertex Pharmaceuticals Inc	460.82	121.40B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	764.93	83.25B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	728.14	46.39B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	320.51	43.41B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	292.94	33.09B	5.36B	287.73M	924.18M	2.5229

Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-05-25	Initiated	B. Riley Securities	Buy
Oct-31-24	Initiated	H.C. Wainwright	Buy
Jul-11-24	Initiated	Cantor Fitzgerald	Overweight
Feb-25-22	Downgrade	Jefferies	Buy → Hold
May-12-21	Initiated	BofA Securities	Buy
Jan-14-21	Downgrade	Citigroup	Buy → Neutral
Oct-29-20	Upgrade	Citigroup	Neutral → Buy
Jun-09-20	Downgrade	Citigroup	Buy → Neutral
Mar-16-20	Downgrade	Oppenheimer	Perform → Underperform
Mar-12-20	Upgrade	Citigroup	Neutral → Buy
Nov-07-19	Downgrade	Citigroup	Buy → Neutral
Aug-01-19	Upgrade	Citigroup	Neutral → Buy
Jul-25-19	Downgrade	Stifel	Buy → Hold
Dec-11-18	Downgrade	Oppenheimer	Outperform → Perform
Dec-04-18	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Dec-04-18	Reiterated	Jefferies	Buy
Nov-08-18	Resumed	Jefferies	Buy
Sep-21-18	Resumed	Oppenheimer	Outperform
May-23-18	Initiated	Citigroup	Buy
Jan-19-18	Initiated	Seaport Global Securities	Buy
Sep-14-17	Reiterated	Piper Jaffray	Overweight
Jun-27-17	Resumed	Piper Jaffray	Overweight
May-26-17	Initiated	H.C. Wainwright	Buy
Apr-12-17	Initiated	Oppenheimer	Outperform
Nov-09-16	Initiated	Aegis Capital	Buy
Oct-06-16	Resumed	Jefferies	Buy

View All

Vanda Pharmaceuticals Inc Stock (VNDA) Latest News

09:00 AM

Truist Financial Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat

09:00 AM

07:10 AM

Truist Securities Initiates Coverage on Vanda Pharmaceuticals (V - GuruFocus

07:10 AM

06:56 AM

Truist initiates Vanda Pharmaceuticals stock at buy on drug pipeline - Investing.com

06:56 AM

06:52 AM

Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target - marketscreener.com

06:52 AM

Mar 04, 2026

Vanda Pharmaceuticals (NASDAQ:VNDA) CMO Joakim Wijkstrom Sells 30,800 Shares - MarketBeat

Mar 04, 2026

Kevin Patrick Moran Sells 42,442 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock - MarketBeat

Mar 04, 2026

Insider Selling: Vanda Pharmaceuticals (NASDAQ:VNDA) SVP Sells 42,434 Shares of Stock - MarketBeat

Mar 04, 2026

Gunther Birznieks Sells 42,431 Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) Stock - MarketBeat

Mar 04, 2026

Insider Selling: Vanda Pharmaceuticals (NASDAQ:VNDA) CEO Sells 156,235 Shares of Stock - MarketBeat

Mar 04, 2026

Vanda Pharmaceuticals (VNDA) SVP sells 42,431 shares to cover RSU tax - Stock Titan

Mar 04, 2026

Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections - Stocktwits

Mar 03, 2026

After years of dispute with FDA, Vanda will get a public hearing for jet lag drug - Endpoints News

Mar 03, 2026

Vanda secures win in regulatory showdown as FDA agrees to review jet lag drug - The Business Journals

Mar 03, 2026

Vanda announces FDA grants landmark hearing for Hetlioz® in jet lag disorder, the first drug approval hearing in over 40 years - marketscreener.com

Mar 03, 2026

Vanda Pharmaceuticals Wins Rare FDA Hearing on HETLIOZ Application for Jet Lag - marketscreener.com

Mar 03, 2026

Vanda Pharmaceuticals (VNDA) Secures Rare FDA Hearing for Hetlio - GuruFocus

Mar 03, 2026

Vanda Announces FDA Grants Landmark Hearing for HETLIOZ in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - Finviz

Mar 03, 2026

Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years - ChartMill

Mar 03, 2026

Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat

Mar 03, 2026

Mar 02, 2026

[144] Vanda Pharmaceuticals Inc. SEC Filing - Stock Titan

Mar 02, 2026

VNDA Earnings History & Surprises | EPS & Revenue Results | VANDA PHARMACEUTICALS INC (NASDAQ:VNDA) - ChartMill

Mar 02, 2026

Feb 27, 2026

EMA Turns Down Vanda’s Iloperidone And Acadia’s Daybu, Backs 12 Others For EU Approval - Citeline News & Insights

Feb 27, 2026

Vanda Pharmaceuticals Receives Negative Opinion From European Medicines Agency's CHMP for Iloperidone - marketscreener.com

Feb 27, 2026

Feb 26, 2026

Vanda Pharmaceuticals to Participate in 2026 Citizens Life Sciences Conference - Intellectia AI

Feb 26, 2026

Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference - ChartMill

Feb 26, 2026

A Look At Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of Bysanti For Bipolar I Disorder And Schizophrenia - simplywall.st

Feb 26, 2026

Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley - Yahoo Finance

Feb 26, 2026